The immune system works through leukocytes interacting with each other, with other cells, with tissue matrices, with infectious agents, and with other antigens. These interactions are mediated by cell-surface glycoproteins and glycolipids. Antibodies against these leukocyte molecules have provided powerful tools for analysis of their structure, function, and distribution. Antibodies have been used widely in hematology, immunology, and pathology, and in research, diagnosis, and therapy. The associated CD nomenclature is commonly used when referring to leukocyte surface molecules and antibodies against them. It provides an essential classification for diagnostic and therapeutic purposes. The most recent (8th) Workshop and Conference on Human Leukocyte Differentiation Antigens (HLDA), held in Adelaide, Australia, in December 2004, allocated 95 new CD designations and made radical changes to its aims and future operational strategy in order to maintain its relevance to modern human biology and clinical practice.

CD molecules 2005: human cell differentiation molecules

MALAVASI, Fabio;
2005-01-01

Abstract

The immune system works through leukocytes interacting with each other, with other cells, with tissue matrices, with infectious agents, and with other antigens. These interactions are mediated by cell-surface glycoproteins and glycolipids. Antibodies against these leukocyte molecules have provided powerful tools for analysis of their structure, function, and distribution. Antibodies have been used widely in hematology, immunology, and pathology, and in research, diagnosis, and therapy. The associated CD nomenclature is commonly used when referring to leukocyte surface molecules and antibodies against them. It provides an essential classification for diagnostic and therapeutic purposes. The most recent (8th) Workshop and Conference on Human Leukocyte Differentiation Antigens (HLDA), held in Adelaide, Australia, in December 2004, allocated 95 new CD designations and made radical changes to its aims and future operational strategy in order to maintain its relevance to modern human biology and clinical practice.
2005
Inglese
Sì, ma tipo non specificato
106(9)
3123
3126
http://bloodjournal.hematologylibrary.org/cgi/reprint/106/9/3123
Epub 2005 Jul 14
CD Workshop; monoclonal antibodies; surface molecules
FRANCIA
SVIZZERA
AUSTRALIA
DANIMARCA
SPAGNA
REPUBBLICA CECA
REGNO UNITO DI GRAN BRETAGNA
AUSTRIA
262
24
ZOLA H; SWART B; NICHOLSON I; AASTED B; BENSUSSAN A; BOUMSELL L; BUCKELY CD; CLARK G; DRBAL K; ENGEL P; HART D; HOREJSI V; ISACKE C; MACARDLE P; MALAV...espandi
info:eu-repo/semantics/article
none
03-CONTRIBUTO IN RIVISTA::03A-Articolo su Rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/42697
Citazioni
  • ???jsp.display-item.citation.pmc??? 23
  • Scopus 102
  • ???jsp.display-item.citation.isi??? 78
social impact